z-logo
open-access-imgOpen Access
Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer
Author(s) -
Anne E. O’Shea,
Guy T. Clifton,
George E. Peoples
Publication year - 2021
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.27998
Subject(s) - medicine , trastuzumab , triple negative breast cancer , oncology , targeted therapy , breast cancer , randomized controlled trial , cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom